MOTS-c Was Found Hiding Inside a Gene That Isn't Supposed to Code for Proteins

Almost all of a cell's protein instructions live in the nucleus. Mitochondria, the compartments that handle a cell's energy, keep their own small separate scrap of DNA, and that scrap has been sequenced, annotated and considered finished for a long time.

In 2015, someone found something in it that had no business being there.

A protein recipe filed in the workshop manual

MOTS-c is a peptide sixteen amino acids long. The interesting part isn't the size. It's the address.

The sequence sits inside the mitochondrial 12S rRNA gene. Ribosomal RNA genes have a well-understood job, and making proteins isn't it. They encode components of the ribosome, which is the machinery a cell uses to build proteins from instructions held elsewhere. The gene describes the workshop, not the thing the workshop makes.

Inside that gene is a short open reading frame, which is the term for a stretch of sequence that reads like instructions for building a protein. A recipe, tucked inside the manual for the equipment.

It turned out not to be a one-off

The same genome holds another one. Humanin is a peptide of twenty-four amino acids, encoded within a different region of that same mitochondrial DNA. It shows up in the exercise study our research write-up cites alongside MOTS-c.

Two peptides, both spelled out inside a genome small enough that people had reasonably assumed it held no more surprises. That's the discovery worth the attention: not one odd molecule, but the realization that a finished-looking piece of biology wasn't finished.

What a sequence in a database actually proves

The most careful line in our own write-up of this is a caution, and it's the kind of thing that usually gets skipped in the excitement. A database entry confirms a sequence. It does not confirm that the peptide is translated inside a living cell.

That gap matters. Finding a protein-shaped stretch of sequence tells you the instructions are present. It doesn't tell you that a cell reads them, that it builds the thing, or that the thing does anything once built. Those are three further questions, each needing its own evidence, and running them together is the easiest mistake to make with a find like this one. The sequence itself is on record and printed in full on the compound's molecular profile.

The chemistry databases haven't entirely settled it either

There's a smaller sign of how recent all this is, and it turns up in the paperwork rather than the biology.

Look the compound up by its registry number and you get two records back rather than one. They describe the same molecule, but one of them is internally inconsistent: it carries the name of a salt form while listing the makeup of the plain peptide. That is not a scandal, and it changes nothing about what the molecule is. It's just what the record-keeping looks like for something that arrived recently enough that the reference infrastructure is still catching up with it.

Eleven years on, the argument is about what it is

You would expect the identity question to be settled by now. It isn't, and that's the second interesting thing here.

A 2026 paper reframes MOTS-c as a mitochondrial-encoded, interferon-linked host defense peptide, meaning something closer to a part of the cell's response to infection. That is a materially different identity from the metabolic regulator described in the original work, which is the reading that puts it among the metabolic compounds in this catalogue.

Neither account has been retired. A molecule discovered in 2015 is still having its basic job description revised in 2026. That's roughly what you'd expect from something that arrived without a category to sit in.

From unknown to explicitly named in eleven years

Here's a measure of how fast this went. In 2015 the molecule was a sequence nobody had noticed. By 2026 it is named on the World Anti-Doping Agency's Prohibited List, in the section covering hormone and metabolic modulators, on the basis of a proposed mechanism. Substances in that section are prohibited at all times rather than only in competition.

That's a decade from "this wasn't in the catalogue of known genes" to "this is on the list by name." It's worth noting what the listing is and isn't: it groups substances by proposed mechanism, so sharing an entry with another compound transfers no findings between them. Any athlete needing certainty should get a binding determination from their own anti-doping organization rather than reading one off an article.

The field is still at the hypothesis-generating stage

One more marker of how early this all is. A short published commentary proposed, as a hypothesis, that a particular variant in the stretch of mitochondrial DNA that encodes MOTS-c might contribute to longevity in one population. The variant is specific to Northeast Asian populations, and the commentary's own language is that more research is needed.

It's worth being precise about what that is and isn't. It's a proposal about a naturally occurring difference in people's DNA, published as a hypothesis rather than a finding, and it says nothing whatsoever about giving anyone the peptide. Fields with a settled picture don't generate papers like that. Fields eleven years old do.

Where this story stops

Where a molecule came from and what it does in a person are two different questions, and this is only the first one. The gap between them is measurable here: the discovery paper is from 2015, and the first registered trial to actually administer MOTS-c to people began recruiting in February 2026. Eleven years from finding a sequence to giving it to a participant, and that trial has reported nothing yet.

The second question has its own page, and it's a genuinely separate read. What the MOTS-c studies actually show covers the animal work, the human biomarker studies, and what has and hasn't been tested.

What stays with us from the discovery side is smaller and stranger. A stretch of DNA that had been read, labelled and filed as complete still had something in it. It took until 2015 for anyone to look in that particular place, and the looking isn't finished.

---

MOTS-c is a research compound, supplied for laboratory research use only.